Aviragen Therapeutics

Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals Inc., is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options. Its product candidates include vapendavir, which is an oral treatment for human rhinovirus (HRV) infections in moderate-to-severe asthmatics that is being evaluated in its Phase IIb SPIRITUS trial; BTA074, a Phase II topical antiviral treatment for genital warts caused by human papillomavirus (HPV) types 6 and 11; BTA585, an oral fusion (F) protein inhibitor in Phase IIa development for the treatment and prevention of respiratory syncytial virus (RSV)-A and RSV-B infections, and laninamivir octanoate in Phase II development for the treatment of influenza A and B infections. It also has preclinical RSV non-fusion inhibitor program.
Type
Public
HQ
Alpharetta, US
Employees
19 (est)
Aviragen Therapeutics has headquartered in Alpharetta, US

Aviragen Therapeutics Locations

Alpharetta, US

Aviragen Therapeutics Metrics

Aviragen Therapeutics Summary

Market capitalization

$50.6 M

Closing share price

$1.31
Aviragen Therapeutics's latest market capitalization is $50.6 M.

Aviragen Therapeutics Market Value History

Aviragen Therapeutics News

Aviragen Therapeutics Company Life

You may also be interested in